Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | GALR2 | O43603 | 9/20 | 0.36 |
| ▸ | GALR1 | P47211 | 7/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3240505 | 0.88 | MAPT (0.39) | POLBMAPTNPSR1GALR2GALR1 | |
| SCHEMBL8253255 | 0.87 | LMNA (0.41) | POLBMAPTNPSR1GALR2GALR1 | |
| SCHEMBL8256650 | 0.85 | MAPT (0.45) | POLBMAPTNPSR1GALR2GALR1 | |
| SCHEMBL8254467 | 0.82 | MAPT (0.48) | POLBMAPTNPSR1GALR2GALR1 | |
| SCHEMBL8253195 | 0.81 | MAPT (0.48) | POLBMAPTNPSR1GALR2GALR1 | |
| SCHEMBL8256940 | 0.80 | MAPT (0.43) | POLBMAPTNPSR1GALR2GALR1 | |
| SCHEMBL8253243 | 0.79 | MAPT (0.39) | POLBMAPTNPSR1GALR2GALR1 | |
| SCHEMBL8256921 | 0.77 | GALR2 (0.56) | POLBMAPTGALR2GALR1HTR2A | |
| SCHEMBL13596142 | 0.77 | GALR1 (0.43) | POLBMAPTGALR2GALR1LMNA | |
| SCHEMBL8254469 | 0.77 | SMN1; SMN2 (0.40) | POLBMAPTNPSR1GALR2GALR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082587-A1 | 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety | H. LUNDBECK A/S (DK) | 2004-04-29 | — | — | US | disclosed |
| US-20040082587-A1 | 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety | H. LUNDBECK A/S (DK) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082587-A1 | 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety | GALR3, GALR2, GALR1 | POLB 2882/4885MAPT 2638/4885NPSR1 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.